Eligo Bioscience
Bringing gene editing to the microbiome
Eligo develops first-in-class proprietary modalities that enable the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology allows for the first time the in-situ modulation of the microbiome’s composition and function to address human disease with an unprecedented precision.
The human body harbors more than 250 million bacterial genes
The interactions between the gene repertoire of the microbiome and the immune system of the host play a pivotal role in health and disease.
The presence or absence of a single bacterial gene can trigger or aggravate a variety of diseases
This genetic causality is being demonstrated in a growing number of therapeutic areas
Introducing our GEM (Gene Editing of the Microbiome) platform
A first-in-class proprietary platform to edit the microbiome gene repertoire in vivo
